Share
RIDGEFIELD PARK, NJ — Seeger Weiss is pleased to announce that partner Parvin K. Aminolroaya has been appointed to serve as plaintiffs’ co-lead counsel in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation by the honorable Judge Gene E. K. Pratter. This litigation consolidates dozens of lawsuits against drugmakers Novo Nordisk and Eli Lilly filed by patients who took Ozempic, Wegovy, Mounjaro, and other similar medications and developed serious conditions, including gastroparesis, ileus, and intestinal blockage.
Parvin is an emerging leader in the plaintiffs’ bar with a focus on product liability and complex litigation. She played an instrumental role in the Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation from inception to the settlement phase. As a result of her work, many women who suffered permanent eye damage from the interstitial cystitis medication received justice and compensation for their injuries.
Previously, Parvin worked on multiple bellwether trial teams in the Testosterone Replacement Therapy Litigation and the 3M Earplug Litigation. Her work on the 3M litigation included the 11th bellwether trial, which resulted in a $110M verdict for two veterans who suffered from hearing loss and tinnitus caused by defective 3M earplugs. She also played an important role in the National Prescription Opiate Litigation, the Volkswagen “Clean Diesel” Litigation, and the Bernard Madoff Securities Fraud Litigation.
In a joint statement, Plaintiffs’ Co-Lead Counsel in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (Paul Pennock of Morgan & Morgan, Parvin K. Aminolroaya of Seeger Weiss, Jonathan Orent of Motley Rice, and Sarah Ruane of Wagstaff & Cartmell) said:
“We are honored to have been appointed by Judge Pratter to lead one of the most significant and consequential pharmaceutical injury cases of our time against the manufacturers of diabetes and weight loss drugs such as Ozempic and Wegovy. The people we represent suffered serious injuries because of these medications, which the defendants aggressively marketed without properly disclosing dangerous gastrointestinal side effects or studying the impact of long-term use on patients’ health. We’re committed to working together to hold the companies accountable for their reckless disregard for patient safety.”
Since the introduction of Ozempic in 2017, Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) medications developed and manufactured by Novo Nordisk and Eli Lilly have been widely prescribed for treating diabetes and provided off-label to patients to promote weight loss. However, reports from patients and recent epidemiological studies have shown that these drugs can also cause serious conditions such as stomach paralysis (gastroparesis), ileus, intestinal blockage, and pulmonary aspiration while under anesthesia.
Novo Nordisk and Eli Lilly are facing dozens of lawsuits filed by people who developed severe complications after taking their GLP-1 RA medications, often requiring hospitalization or immediate medical intervention. Plaintiffs allege the manufacturers knew or should have known about severe gastrointestinal side effects caused by GLP-1 RAs, but failed to properly warn patients on labels and downplayed the risks in advertising and marketing for these medications. The manufacturers also failed to warn doctors and patients about the dangers of their medication, all while making millions of dollars through deceptive marketing practices that have resulted in hundreds of thousands of prescriptions nationwide.
Seeger Weiss represents people who used GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and other GLP-1 RAs, and experienced injuries such as ileus, intestinal blockage, or gastroparesis requiring hospitalization, and pulmonary aspiration during surgery.
One of the nation’s preeminent plaintiffs’ law firms, Seeger Weiss is best known for multidistrict mass torts and class actions in both state and federal court—and especially for taking those cases to trial. With the resources and dedication to take on the world’s largest corporations, the firm has an impressive track record of victories against companies like Merck, Monsanto, and 3M—and a reputation for sticking with a case from beginning to end. From offices in New York, New Jersey, Pennsylvania, and Massachusetts, the firm has represented over 10,000 individuals, companies, and governments across the United States who have been injured or defrauded on a massive scale. Since its founding in 1999, it has led many of the most complex and high-profile cases in the country: the National Prescription Opiate Litigation, which the Washington Post called “the largest federal court case in U.S. history”; the ongoing “Dieselgate” scandal; the sprawling multistate litigation on behalf of survivors of child sexual abuse; and the history-making National Football League Players’ Concussion Injury Litigation.
Prior results do not guarantee or predict a similar outcome in any future matter.